Malignant schwannoma following treatment for Hodgkin's disease.
Two cases of malignant schwannoma are reported 13 and 15 years following combined modality treatment for Hodgkin's disease. Both patients survived for only 15 months. The aetiology of this rare condition is discussed.
Fisher
P M
PM
Cookridge Hospital, Leeds, UK.
Dodwell
D J
DJ
Bridges
L R
LR
Cartwright
S C
SC
Stone
J
J
D000293:Adolescent; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002648:Child; D003131:Combined Modality Therapy; D005260:Female; D006689:Hodgkin Disease / Q000188:drug therapy* / Q000532:radiotherapy*; D006801:Humans; D008297:Male; D008466:Mechlorethamine / Q000008:administration & dosage; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy; D016609:Neoplasms, Second Primary / Q000473:pathology*; D009442:Neurilemmoma / Q000473:pathology*; D011241:Prednisone / Q000008:administration & dosage; D011344:Procarbazine / Q000008:administration & dosage; D013120:Spinal Cord Neoplasms / Q000473:pathology*; D014750:Vincristine / Q000008:administration & dosage
D011344:Procarbazine; D008466:Mechlorethamine; D014750:Vincristine; D011241:Prednisone